Company profile
Prokarium Limited
Home - Prokarium
Applications
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts filed
AccountsLast accounts made up date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Change Person Director Company With Change Date
OfficersCH01 | Transaction MzQzMzQ3OTA2OGFkaXF6a2N4
Published 27 Aug 2024 14:45
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
Spin-out company developing vaccines
Project impact
company based on live attenuated vaccines
Public funding
Projects
Next generation living cures for cancer immunotherapy
1 Aug 2024 to 31 Jul 2025
Cancer occurs when cells in the body accumulate genetic mutations that prompt them to grow uncontrollably, affecting normal body functions and potentially leading to death. Acquiring such mutations, and therefore developing a cancer, is more probable as we age. It is estimated that 1 in 2 people will experience cancer in their lifetime. Most standard canc...
Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)
1 Jan 2024 to 31 Dec 2025
Bladder Cancer (BC) affects more than 550,000 people globally every year. With the highest recurrence rate of any known cancer (80%), it is one of the most expensive for the NHS to treat, costing £65M pa (CRUK). Current immunotherapy treatments based on the weakened strain of _Mycobacterium bovis_ (BCG) present a significant challenge, with substantial im...
Intracellular bacterial delivery of therapeutic proteins for treatment of cancer
1 Aug 2023 to 31 Jul 2024
Cancer occurs when cells in the body accumulate genetic mutations that prompt them to grow uncontrollably, affecting normal body functions and potentially leading to death. Acquiring such mutations, and therefore developing a cancer, is more probable as we age. It is estimated that 1 in 2 people will experience cancer in their lifetime. Most standard canc...
Newton Fund - Development of an oral, thermostable enteric fever vaccine: saving lives and supporting tourism in Mexico
1 Nov 2016 to 31 Mar 2019
Enteric fever is caused by two types of bacteria: Salmonella Typhi (typhoid) and Salmonella Paratyphi (paratyphoid), contracted from contaminated food or water. Although there are vaccines to prevent typhoid, there is no vaccine for paratyphoid which is a growing problem globally. With nearly 27 million global cases of enteric fever each year, Entervax™, ...
Rapid, simple manufacture and clinical evaluation of an oral plague vaccine
1 Oct 2016 to 31 Dec 2019
As recent disease outbreaks show, the world needs to be faster and better at developing, manufacturing, testing and distributing vaccines. Prokarium, a UK-based vaccine development company focusing on oral vaccines, can move from bench to clinic 6-12 months faster compared to most injectable vaccines, use the same manufacturing process to produce a wide r...
An affordable, oral vaccine against mosquito- and sexually-transmitted Zika virus
1 Oct 2016 to 30 Sep 2017
In February 2016 the WHO declared the Zika virus (ZIKV) to be a “Public Health Emergency of International Concern”. Experts now believe ZIKV is linked to a broad set of complications in pregnancy, including miscarriage, stillbirth, premature birth and eye problems with 29% of scans showing abnormalities in babies in the womb, including growth restrictions...
A novel prophylactic vaccine and delivery platform to prevent Clostridium difficile infections
1 May 2016 to 31 Oct 2017
C. difficile infection (CDI) causes severe diarrhoea in hospital patients after treatment with broad-spectrumantibiotics. CDI can be successfully treated with specific antibiotics, but infection and diarrhoea re-occurs in upto 3 out of 10 patients and on average 2 of these will die. A vaccine could prevent CDI but none is currentlyavailable. The vaccines ...
Breaking the cold chain for oral recombinant vaccines
1 Apr 2015 to 30 Jun 2016
New vaccines are made from proteins that have to be injected using a needle. The process of making these proteins is very expensive and different for each vaccine. They cannot be put into tablets because they would be digested in the gut, and they need to be refrigerated and transported around developing countries via a distribution network called the col...
Engineering immune-cell-targeting bacteria to express vaccines from within the body
1 Apr 2013 to 30 Sep 2014
Prokarium Ltd of Keele, Staffordshire, has invented Vaxonella, a synthetic biology platform that promises to eliminate the need for needles for many vaccines. This is not only convenient for UK travellers going abroad, but will be essential in preventing diseases in rural areas where people do not have access to medical professionals. Vaxonella is based o...